Connecticut residents seeking new options for obesity treatment are hearing a clear message from Yale School of Medicine. Dr. Ania Jastreboff, an endocrinologist who leads the university’s Obesity Research Center, says GLP-1 medications have moved from diabetes treatment to a powerful tool for weight management.
How GLP-1 drugs work
GLP-1, short for glucagon‑like peptide‑1, is a hormone that regulates appetite and blood sugar. When prescribed for type‑2 diabetes two decades ago, doctors noticed a side effect: patients lost weight. That observation sparked research into using the drug class specifically for obesity.
According to a recent Gallup survey, 11 % of U.S. adults are now taking GLP-1 medications for weight loss, up from 3 % in 2024. Dr. Jastreboff emphasizes that the drugs are most effective when paired with a balanced diet and regular physical activity.
Medical perspective on obesity
“Obesity is not a choice or a moral failing,” Dr. Jastreboff told NBC Connecticut. “It is a disease with clear underlying biology.” She argues that framing the condition as a health issue rather than a personal shortcoming helps patients receive compassionate care.
In clinical trials at Yale, participants have reported dramatic improvements. One trial participant, restaurant‑industry worker Vincent Perricone, lost nearly 100 pounds, regained energy, and saw relief from joint pain. “I got a big chunk of my life back,” he said.
Safety warnings and compounded products
While the benefits are promising, Dr. Jastreboff cautions Connecticut patients about unregulated compounded versions of GLP‑1 drugs. The Alliance for Pharmacy Compounding notes a surge in demand, leading some pharmacies to produce copies in regulatory gray areas. The FDA has issued safety warnings because compounded substances are not subject to the same testing standards.
Reports from the American Poison Center indicate that some patients have unintentionally taken doses ten times higher than recommended when using compounded products. Dr. Jastreboff advises a cautious titration approach: start with the lowest dose, increase slowly, and monitor for side effects under a physician’s guidance.
Looking ahead
Yale’s Obesity Research Center continues to conduct trials of novel GLP‑1 therapies, aiming to expand the toolbox for physicians treating obesity. Dr. Jastreboff believes that broader access to safe, evidence‑based medications could help prevent or mitigate up to 200 other diseases linked to excess weight.
For Connecticut residents considering GLP‑1 treatment, the recommendation is clear: consult a qualified healthcare provider, follow a supervised dosing schedule, and combine medication with lifestyle changes for the best outcomes.
Original reporting: NBC Connecticut — read the source article.
